Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mudra

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Medicinal Chemistry|June 15, 2017
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human DoseTimothy B Durham, Jothirajah Marimuthu, James L Toth, et al.
Journal of Medicinal Chemistry|May 20, 2016
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase InhibitorsMichael R Wiley, Timothy B Durham, Lisa A Adams, et al.
Journal of Medicinal Chemistry|May 1, 2012
Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptorConcepción Pedregal, Elizabeth M Joshi, Miguel A Toledo, et al.
Journal of Medicinal Chemistry|April 1, 2014
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffoldMiguel A Toledo, Concepción Pedregal, Celia Lafuente, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 19, 2003
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytesAjay Madan, Richard A Graham, Kathleen M Carroll, et al.
Drug Discovery Today|May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspectiveHarvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug DesignSpencer B Jones, Lance A Pfeifer, Thomas J Bleisch, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2017
Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1Katherine M Partridge, Stephen Antonysamy, Shobha N Bhattachar, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Medicinal Chemistry|June 15, 2017
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human DoseTimothy B Durham, Jothirajah Marimuthu, James L Toth, et al.
Journal of Medicinal Chemistry|May 20, 2016
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase InhibitorsMichael R Wiley, Timothy B Durham, Lisa A Adams, et al.
Journal of Medicinal Chemistry|May 1, 2012
Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptorConcepción Pedregal, Elizabeth M Joshi, Miguel A Toledo, et al.
Journal of Medicinal Chemistry|April 1, 2014
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffoldMiguel A Toledo, Concepción Pedregal, Celia Lafuente, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 19, 2003
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytesAjay Madan, Richard A Graham, Kathleen M Carroll, et al.
Drug Discovery Today|May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspectiveHarvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug DesignSpencer B Jones, Lance A Pfeifer, Thomas J Bleisch, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2017
Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1Katherine M Partridge, Stephen Antonysamy, Shobha N Bhattachar, et al.
Pageof 2